BUND FINANCE › Stocks › BIIB
Biogen Inc. (BIIB)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +7.11% above its 50-day average.
- It is +22.12% above its 200-day average (long-term uptrend).
- It sits at 90% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$11.0B | US$10.2B | US$9.8B | US$9.7B | US$9.9B |
| Net income | US$1.6B | US$3.0B | US$1.2B | US$1.6B | US$1.3B |
| EPS (diluted) | 10.40 | 20.87 | 7.97 | 11.19 | 8.79 |
| Gross margin | 80.8% | 77.6% | 74.2% | 76.1% | 75.7% |
| Operating margin | 25.4% | 28.4% | 21.3% | 25.7% | 25.0% |
| Net margin | 14.2% | 30.0% | 11.8% | 16.9% | 13.1% |
| Free cash flow | US$3.4B | US$1.1B | US$1.2B | US$2.5B | US$2.1B |
| Total debt | US$7.6B | US$6.6B | US$7.3B | US$6.6B | US$6.9B |
| Cash | US$2.3B | US$3.4B | US$1.0B | US$2.4B | US$3.0B |
Compound annual growth: revenue -2.6% · net income -4.5% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 107.4x | 20.4x | 27.1x |
| EV / EBITDA | 30.1x | 12.3x | 16.5x |
| Operating margin | 7.6% | — | 3.6% |
| Net margin | 3.4% | — | -0.0% |
| Debt / equity | 0.69 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Biogen Inc.
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an …
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice